Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress
Tóm tắt
Accumulating evidence suggests that activated hepatocytes are involved in the deposition of the excess extracellular matrix during liver fibrosis via the epithelial to mesenchymal transition. Lipid accumulation in hepatocytes are implicated in the pathogenesis of chronic liver injury. CD36 is known to mediate long-chain fatty acid (LCFA) uptake and lipid metabolism. However, it is unclear whether LCFA directly promotes hepatocyte activation and the involved mechanisms have not been fully clarified. Mice were fed with a high fat diet (HFD) and normal hepatocyte cells (Chang liver cells) were treated with palmitic acid (PA) in vivo and in vitro. Real-time polymerase chain reaction (RT-PCR) and western blotting were used to examine the gene and protein expression of molecules involved in hepatic fibrogenesis and hepatocyte activation. CD36 was knocked down by transfecting CD36 siRNA into hepatocyte cells. Hydrogen peroxide (H2O2) and reactive oxygen species (ROS) levels were detected using commercial kits. HFD induced a profibrogenic response and up-regulated CD36 expression in vivo. Analogously, PA increased lipid accumulation and induced human hepatocyte activation in vitro, which was also accompanied by increased CD36 expression. Interestingly, knockdown of CD36 resulted in a reduction of hepatocyte lipid deposition and decreased expression of Acta2 (34% decrease), Vimentin (29% decrease), Desmin (60% decrease), and TGF-β signaling pathway related genes. In addition, HFD and PA increased the production of H2O2 in vivo (48% increase) and in vitro (385% increase), and the antioxidant, NAC, ameliorated PA-induced hepatocyte activation. Furthermore, silencing of CD36 in vitro markedly attenuated PA-induced oxidative stress (H2O2: 41% decrease; ROS: 39% decrease), and the anti-activation effects of CD36 knockdown could be abolished by pretreatment with H2O2. Our study demonstrated that LCFA facilitates hepatocyte activation by up-regulating oxidative stress through CD36, which could be an important mechanism in the development of hepatic fibrosis.
Tài liệu tham khảo
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20(23):7312–24.
Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20(10):2515–32.
Tennakoon AH, Izawa T, Kuwamura M, Yamate J. Pathogenesis of type 2 epithelial to mesenchymal transition (EMT) in renal and hepatic fibrosis. J Clin Medicine. 2016;5(4):1–16.
Chen AP. Acetaldehyde stimulates the activation of latent transforming growth factor-β1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. Biochem J. 2002;368:683–93.
Zhao YL, Zhu RT, Sun YL. Epithelial-mesenchymal transition in liver fibrosis. Biomedical Reports. 2016;4:269–74.
Lua I, Asahina K. The role of mesothelial cells in liver development, injury, and regeneration. Gut and Liver. 2016;10(2):166–76.
Friedman SL. Stellate cells: a moving target in hepatic Fibrogenesis. Hepatology. 2004;40(5):1041–3.
Wu K, Ye CH, Lin L, et al. Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. Clin Science. 2016;130:1469–80.
Fausther M, Lavoie EG, Dranoff JA. Contribution of Myofibroblasts of different origins to liver fibrosis. Curr Pathobiol Rep. 2013;1(3):225–30.
Kim SM, Choi JE, et al. RAR-related orphan receptor gamma (ROR-g)mediates epithelial-mesenchymal transition of hepatocytes during hepatic fibrosis. J Cell Biochem. 2017;118:2026–36.
Kaimori A, Potter JJ, Choti M, et al. Histone deacetylase inhibition suppresses the transforming growth factor β1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology. 2010;52(3):1033–45.
Kawano YK, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434–41.
Angulo P, Keach JC, Batts KP. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–62.
Tomita K, Teratani T, Suzuki T, Shimizu M. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology. 2014;59:154–69.
Bechmann LP, Zahn D, Gieseler RK. Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatol Res. 2009;39(6):601–8.
Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Medicine. 2014;46:e99.
Nergiz-Unal R, Rademakers T, et al. CD36 as a multiple-ligand signaling receptor in Atherothrombosis. Car Hem Med Chemistry. 2011;9(1):1–9.
Huang J, Zhao L, Yang P, et al. Genome-wide transcriptome analysis of CD36 overexpression in HepG2.2.15 cells to explore its regulatory role in metabolism and the hepatitis B virus life cycle. PLoS One. 2016;11(10):e0164787.
Scihneiderhan W, Schmid-kotsas A, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology. 2001;34(4):729–37.
Scicchitanoa P, Camelib M, Maiello M, et al. Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014;6:11–32.
Zhao L, Zhong S, Qu HY, et al. Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci Rep. 2014;5:10222.
Nitta T, Kim JS, Mohuczy D, et al. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology. 2008;48(3):909–19.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8.
Kaimori A, Potter J, Kaimori JY, et al. Transforming growth factor-β1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem. 2007;282(30):22089–101.
Tsukamoto H, Horne W, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995;96:620–30.
Spahis S, Delvin E, Borys JM, et al. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Anti Red Signaling. 2016;10:e6776.
Li W, Febbraio M, Reddy SP, et al. CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest. 2010;120(11):3996–4006.
Colina MEM, Campos SS, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Hepatology. 2011;60:1394–402.
Zhong S, Zhao L, Wang Y, et al. Cluster of differentiation 36 deficiency aggravates macrophage infiltration and hepatic inflammation by upregulating monocyte chemotactic protein-1 expression of hepatocytes through histone deacetylase 2-dependent pathway. Antioxid Redox Signal. 2017;27(4):201–14.